VT-1011 Drug Market
"VT-1011 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about VT-1011 for Presbyopia in the 7MM. A detailed picture of the VT-1011 for Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the VT-1011 for Presbyopia. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VT-1011 market forecast, analysis for Presbyopia in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Presbyopia.
VT-1011 Drug Summary
VT-1011 [Brimochol (carbachol + brimonidine tartrate)] is a lead investigational proprietary pupil-modulating eye drop for adults who suffer from presbyopia. The company is investigating the drug as a prescription to correct the loss of near vision.
Carbachol is a cholinergic agent that increases the depth of field, while brimonidine tartrate is an alpha-2 agonist that prevents iris dilation and inhibits ciliary body contraction. Together they produce a “pinhole effect,” which reduces the size of the pupil so that only centrally focused light rays can enter the eye, thereby sharpening distant and near images while minimizing side effects. Brimonidine mitigates the side effects typically associated with cholinergic agents on the ciliary body, such as headache, brow ache, and myopic shift. Additionally, it also prolongs the pinhole effect of carbachol on the iris sphincter muscle by altering aqueous dynamics.
Brimochol, which is being developed by Visus Therapeutics, is the first presbyopia eye drop with the potential to last a minimum of 8 hours.
Currently the company has initiated a Phase III clinical trial for the safety and efficacy study of Brimochol in subjects with emmetropic phakic and pseudophakic presbyopia along with Phase III trials (BRIO-I and BRIO-II) for BRIMOCHOL PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.
Scope of the VT-1011 Drug Market Report
The report provides insights into:
• A comprehensive product overview including the VT-1011 description, mechanism of action, dosage and administration, research and development activities in Presbyopia.
• Elaborated details on VT-1011 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VT-1011 research and development activity in Presbyopia in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VT-1011.
• The report contains forecasted sales of VT-1011 for Presbyopia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Presbyopia.
• The report also features the SWOT analysis with analyst views for VT-1011 in Presbyopia.
VT-1011 Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VT-1011 Analytical Perspective by DelveInsight
• In-depth VT-1011 Market Assessment
This report provides a detailed market assessment of VT-1011 in Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
• VT-1011 Clinical Assessment
The report provides the clinical trials information of VT-1011 in Presbyopia covering trial interventions, trial conditions, trial status, start and completion dates.
VT-1011 Drug Market Report Highlights
• In the coming years, the market scenario for Presbyopia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VT-1011 dominance.
• Other emerging products for Presbyopia are expected to give tough market competition to VT-1011 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VT-1011 in Presbyopia.
• Our in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VT-1011 in Presbyopia.
Key Questions
• What is the product type, route of administration and mechanism of action of VT-1011?
• What is the clinical trial status of the study related to VT-1011 in Presbyopia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VT-1011 development?
• What are the key designations that have been granted to VT-1011 for Presbyopia?
• What is the forecasted market scenario of VT-1011 for Presbyopia?
• What are the forecasted sales of VT-1011 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Presbyopia and how are they giving competition to VT-1011 for Presbyopia?
• Which are the late-stage emerging therapies under development for the treatment of Presbyopia?
